Abstract 4364307: VS-041, a narrow-spectrum, matrix metalloproteinase (MMP) inhibitor and novel drug candidate for heart failure with preserved ejection fraction (HFpEF), demonstrates target engagement and is safe and well-tolerated in healthy participants.
Year: 2025
Type: conference-abstract
Source: Circulation
Authors: Noreen Henig, Wieslaw Bochenek, Magdalena Krupa, Joel Berger, Benjamin Pratt, John Vekich, Christopher Larson, Artur Plonowski
Institution: Vasa Therapeutics Sp. z o.o. (Poland)
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415799529
Cites:
Cited by:
Related to: